茵栀黄口服液联合地塞米松治疗妊娠期肝内胆汁淤积症疗效以及患者血浆生化、免疫指标的影响
|
摘要
目的分析茵栀黄口服液、地塞米松用于妊娠期肝内胆汁淤积(ICP)治疗的可行性。方法取2018年1月至2018年12月ICP孕妇为研究对象,人数100例,随机分组,对照组50例、观察组50例(行中西药联合治疗),观察两组疗效差异,观察患者生化指标治疗前后变化,统计妊娠结局。结果治疗后观察组ALT、TBA、IL-12水平低于对照组,P<0.05;观察组治疗率为94.0%高于对照组84.0%,P<0.05;两组不良妊娠结局统计,观察组发生率为12.0%低于对照组24.0%,P<0.05。结论 ICP患者临床治疗中应用地塞米松、茵栀黄口服液,能有效提高治疗效果,促肝功能改善,减少不良妊娠结局发生。
Objective To analyze the feasibility of oral liquid combined with dexamethasone in the treatment of ICP(intrahepatic cholestasis of pregnancy). Methods 100 cases of ICP were selected for study from January 2018 to December 2018. They were divided into a control group(n=50) and an observation group(n=50) randomly and evenly.Western medicine combined with TCM treatment was adopted in the observation group. Then the effectiveness and the biochemical indicators before and after treatment were compared between the two groups and the pregnancy outcome was recorded. Results After treatment, the levels of ALT, TBA and IL-12 in the observation group were lower than those in the control group(P<0.05). The effective rate in the observation group was 94.0 %, higher than 84.0 % of the control group(P<0.05). As for the adverse pregnancy outcomes, the incidence of observation group is 12.0%, lower than 24.0% of the control group(P<0.05). Conclusion The application of dexamethasone and Yinzhihuang oral liquid in the clinical treatment of ICP can effectively improve the therapeutic effects, improve liver function and reduce the incidence of adverse pregnancy outcomes.
Objective To analyze the feasibility of oral liquid combined with dexamethasone in the treatment of ICP(intrahepatic cholestasis of pregnancy). Methods 100 cases of ICP were selected for study from January 2018 to December 2018. They were divided into a control group(n=50) and an observation group(n=50) randomly and evenly.Western medicine combined with TCM treatment was adopted in the observation group. Then the effectiveness and the biochemical indicators before and after treatment were compared between the two groups and the pregnancy outcome was recorded. Results After treatment, the levels of ALT, TBA and IL-12 in the observation group were lower than those in the control group(P<0.05). The effective rate in the observation group was 94.0 %, higher than 84.0 % of the control group(P<0.05). As for the adverse pregnancy outcomes, the incidence of observation group is 12.0%, lower than 24.0% of the control group(P<0.05). Conclusion The application of dexamethasone and Yinzhihuang oral liquid in the clinical treatment of ICP can effectively improve the therapeutic effects, improve liver function and reduce the incidence of adverse pregnancy outcomes.
引文
[1]李华,张利平,高霞,等.地塞米松联合熊脱氧胆酸治疗妊娠期肝内胆汁淤积的临床疗效及对血清PLTP IL-18水平的影响[J].河北医学,2018,24(08):1254-1258.
[2]徐丽燕.茵栀黄口服液在妊娠期肝内胆汁淤积症治疗中应用效果观察[J].中国妇幼健康研究,2017,28(S4):353.
[3]赵薇,王玫,任景芳.地塞米松联合思美泰、熊去氧胆酸治疗妊娠期肝内胆汁淤积症疗效观察[J].现代中西医结合杂志,2015,24(20):2240-2242.
[4]李桂香,刘玲玲,毛玉芳,等.丁二磺酸腺苷蛋氨酸联合地塞米松对妊娠期肝内胆汁淤积症患者肝功能及血清TNF-α,IL-12水平的影响[J].现代生物医学进展,2017,17(19):3765-3768.
[5]彭书华.熊去氧胆酸与地塞米松联合应用治疗妊娠期肝内胆汁淤积症的疗效分析[J].医学理论与实践,2013,26(08):1000-1001.
[2]徐丽燕.茵栀黄口服液在妊娠期肝内胆汁淤积症治疗中应用效果观察[J].中国妇幼健康研究,2017,28(S4):353.
[3]赵薇,王玫,任景芳.地塞米松联合思美泰、熊去氧胆酸治疗妊娠期肝内胆汁淤积症疗效观察[J].现代中西医结合杂志,2015,24(20):2240-2242.
[4]李桂香,刘玲玲,毛玉芳,等.丁二磺酸腺苷蛋氨酸联合地塞米松对妊娠期肝内胆汁淤积症患者肝功能及血清TNF-α,IL-12水平的影响[J].现代生物医学进展,2017,17(19):3765-3768.
[5]彭书华.熊去氧胆酸与地塞米松联合应用治疗妊娠期肝内胆汁淤积症的疗效分析[J].医学理论与实践,2013,26(08):1000-1001.